PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.
The conversation is about sourcing and using topical melatonin for retrograde alopecia. Users discuss purchasing options and potential benefits for hair growth.
The user is using finasteride, minoxidil, and ketoconazole shampoo for hair loss and stopped derma stamping to prepare for a future hair transplant. They are considering adding tretinoin to their treatment.
Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.
Considering a hair transplant, using Pyrilutamide, the potential availability of CosmeRNA, and the significance of taking Minoxidil and Finasteride for long-term results.
The conversation discusses alternatives to finasteride for hair loss, including topical treatments like minoxidil, RU58841, CB-03-01, and dutasteride. Users also mention other options like alfatradiol, topical caffeine, and mesotherapy, while expressing concerns about side effects and the effectiveness of these treatments.
Hair loss treatments, specifically the use of Alfatradiol as an over-the-counter topical 5AR inhibitor that has been shown to be effective in stopping hair loss without side effects. Other treatments discussed include Minoxidil, finasteride and RU58841.
A dermatologist prescribed Betnovate scalp, a corticosteroid, for a 21-year-old male's hair loss due to DHT. The individual is considering using Nizoral shampoo, topical finasteride, a derma roller, and minoxidil, but is unsure about the effectiveness of two other products suggested by the dermatologist.
PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.